ERBB2 and neoplasm: In conclusion, patients with worse prognostic profile based on ER and HER2 status are more likely to respond to neoadjuvant chemotherapy in the real‐world setting in Asia and pCR is associated with better overall survival especially for patients with ER‐negative tumor.